Skip to content

Study · Non-randomized trial · 1977

6 results

Impaired responsiveness to the effect of glucagon on plasma adenosine 3':5'-cyclic monophosphate in normal man.

Hendy GN, Tomlinson S, O'Riordan JL

European journal of clinical investigation1 Jun 1977Cited by 14 (Europe PMC)

PMID196859 (opens in a new tab)DOI10.1111/j.1365-2362.1977.tb01591.x (opens in a new tab)PepBankPUB-00196859
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialMechanism

    In humans, injected glucagon produced a dose-dependent increase in plasma cyclic AMP concentration.

    In plain wordsIn people, injected glucagon increased plasma cyclic AMP as the dose increased.

    Peptide
    Glucagon
    Outcome
    IncreasePlasma cyclic AMP dose response
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    10-150 microgram · injectionAs given in this study (human).

    Source sentences

    Summary
    Small doses (10-150 microgram; 3-45 nmol) of glucagon caused a dose-dependent increase in plasma adenosine 3':5'-cyclic monophosphate (cyclic AMP) concentration when injected into man.
  2. 02HumanNon-randomized trialMechanism

    In normal subjects, glucagon infusion initially increased plasma cyclic AMP, which then declined despite continued infusion.

    In plain wordsIn normal subjects, plasma cyclic AMP first increased and then declined during continued glucagon infusion.

    Peptide
    Glucagon
    Outcome
    MixedPlasma cyclic AMP during infusion
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    75 ng min-1 kg-1 · infusion · 2 hAs given in this study (human).

    Source sentences

    Summary
    Infusion of glucagon (75 ng min-1 kg-1) for 2 h into normal subjects resulted in an initial increase in plasma cyclic AMP concentration, then a decline despite continuation of the hormone infusion and maintenance of high concentrations of circulating immunoreactive glucagon.
  3. 03HumanNon-randomized trialPharmacokinetics

    In normal subjects, circulating immunoreactive glucagon remained high during glucagon infusion despite declining cyclic AMP.

    In plain wordsIn normal subjects, blood glucagon remained high during infusion while cyclic AMP declined.

    Peptide
    Glucagon
    Outcome
    IncreaseCirculating immunoreactive glucagon during infusion
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Endocrine and hormones
    Studied dose
    75 ng min-1 kg-1 · infusion · 2 hAs given in this study (human).

    Source sentences

    Summary
    Infusion of glucagon (75 ng min-1 kg-1) for 2 h into normal subjects resulted in an initial increase in plasma cyclic AMP concentration, then a decline despite continuation of the hormone infusion and maintenance of high concentrations of circulating immunoreactive glucagon.
  4. 04HumanNon-randomized trialMechanism

    In humans, prior glucagon infusion markedly reduced the plasma cyclic AMP increase after a subsequent glucagon injection.

    In plain wordsIn people, glucagon injection increased cyclic AMP less after a glucagon infusion than without a preceding infusion.

    Peptide
    Glucagon
    Outcome
    DecreaseCyclic AMP response after prior glucagon infusion
    Study

    n: not reported in source

    Comparator
    Glucagon injection without preceding glucagon infusion
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated · injectionAs given in this study (human).

    Source sentences

    Summary
    When an injection of glucagon was given at the termination of such an infusion, the subsequent increase in plasma cyclic AMP concentration was markedly reduced when compared to that observed after a control injection which had not been preceded by a glucagon infusion.
  5. 05HumanNon-randomized trialMechanism

    In humans, the plasma cyclic AMP response to glucagon remained normal after bovine parathyroid hormone infusion.

    In plain wordsIn people, the cyclic AMP response to glucagon remained normal after bovine parathyroid hormone infusion.

    Peptide
    Glucagon
    Outcome
    Not applicableCyclic AMP response after bovine parathyroid hormone infusion
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated · injectionAs given in this study (human).

    Source sentences

    Summary
    When the glucagon was injected at the end of an infusion of 1000 MRC units of bovine parathyroid hormone (BPTH) over 2 h, the plasma cyclic AMP response was normal.
  6. 06HumanNon-randomized trialMechanism

    In humans, the response to injected bovine parathyroid hormone remained normal after glucagon infusion.

    In plain wordsIn people, the response to bovine parathyroid hormone remained normal after glucagon infusion.

    Peptide
    Glucagon
    Outcome
    Not applicableCyclic AMP response to bovine parathyroid hormone after glucagon
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Conversely, after infusion of glucagon the response to injected BPTH was normal.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.